[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369152-105":59,"doc-detail-369152-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","radioresistance-in-rectal-cancer-can-nanoparticles-turn-the-tide","Radioresistance in rectal cancer: can nanoparticles turn the tide?","","Rectal cancer accounts for over 35% of the global colorectal cancer burden and is treated distinctly from colon cancer due to anatomical and molecular differences, with neoadjuvant chemoradiotherapy central for locally advanced disease. Despite advances, radioresistance persists as a major barrier linked to poor prognosis. This review revisits key molecular differences between rectal and colon tumors and summarizes the most promising nanomedicines reported to improve neoadjuvant therapy response rates, including approaches that increase intratumoral drug delivery.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/radioresistance-in-rectal-cancer-can-nanoparticles-turn-the-tide/369152/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/radioresistance-in-rectal-cancer-can-nanoparticles-turn-the-tide/369152.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is rectal cancer treated differently from colon cancer?","Question",{"text":112,"@type":113},"Rectal and colon tumors differ anatomically and molecularly, leading to distinct treatment strategies. Neoadjuvant chemoradiotherapy is pivotal for locally advanced rectal cancer control.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the main obstacle addressed in the review?",{"text":117,"@type":113},"Radioresistance remains a major barrier, often correlated with poor prognosis, limiting response to neoadjuvant chemoradiotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"How can nanoparticles improve radiotherapy outcomes in rectal cancer?",{"text":121,"@type":113},"Nanoparticles can exploit the enhanced permeability and retention (EPR) effect for tumor accumulation and can be surface-modified with ligands to enhance targeting, potentially improving radiotherapy response and intratumoral drug delivery.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369152,1790292184,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Coelho et al. Molecular Cancer (2025) 24:35 [https://doi.org/10.1186/s12943-025-02232-x](https://doi.org/10.1186/s12943-025-02232-x)  \nMolecular Cancer  \n REVIEW Open Access  \nRadioresistance in rectal cancer: can nanoparticles turn the tide?  \nDiogo Coelho1,2,3, Diogo Estêvão 1,2,4,5, Maria José Oliveira1,2,5 and Bruno Sarmento1,2,3*  \nAbstract  \nRectal cancer accounts for over 35% of the worldwide colorectal cancer burden representing a distinctive subset of cancers from those arising in the colon. Colorectal cancers exhibit a continuum of traits that differ with their location in the large intestine. Due to anatomical and molecular differences, rectal cancer is treated differently from colon cancer, with neoadjuvant chemoradiotherapy playing a pivotal role in the control of the locally advanced disease. However, radioresistance remains a major obstacle often correlated with poor prognosis. Multifunctional nanomedicines offer a promising approach to improve radiotherapy response rates, as well as to increase the intratumoral concentration of chemotherapeutic agents, such as 5-Fluorouracil. Here, we revise the main molecular differences between rectal and colon tumors, exploring the complex orchestration beyond rectal cancer radioresistance and the most promising nanomedicines reported in the literature to improve neoadjuvant therapy response rates.  \nKeywords Rectal cancer, Treatment, Chemoradiotherapy, Radioresistance, Nanomedicines  \n*Correspondence:  \nBruno Sarmento  \n[bruno.sarmento@i3s.up.pt](bruno.sarmento@i3s.up.pt)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nCoelho et al. Molecular Cancer (2025) 24:35 Page 2 of 23  \nGraphical Abstract  \nBackground  \nCancer is a heterogeneous disease characterized by a multiplicity of cellular and acellular components, driving gene mutations responsible for the well-described hallmarks proposed by Hanahan and Weinberg that are crucial for tumor cells to shift from a normal toa neoplastic state [1, 2] . Colorectal cancer (CRC) is a global public health challenge, responsible for almost 2 million new cancer cases and 10% of all cancerrelated deaths worldwide [3] . Moreover, CRC burden is projected to rise by 63% in the next two decades [4] . Within CRC, rectal cancer (RC) accounts for more than 35% of all new CRC cases and deaths, thus contributing to the high incidence and mortality rates of gastrointestinal malignancies [3] . Alarmingly, incidence among young adults, who are not currently included in routine screening guidelines, have nearly doubled over the last decades, positioning CRC as the leading cause of cancer death among young adult men [5] . Notably, RC is a major driver of this concerning trend, and by the end of the current decade, an increase of 124% in RC patients, is expected, under the age of 35 years [6] . Furthermore, nearly a quarter of all new RC cases are expected to be diagnosed in individuals younger than 50 years of age, often at an advanced stage [6] . In addition, males more f","cbCaiaya5rMEP4yR","https://ap.wps.com/l/cbCaiaya5rMEP4yR","pdf",5447450,23,"English","# Background\n## Rectal cancer burden and unmet clinical needs\n## Neoadjuvant radiotherapy and radioresistance challenge\n# Nanoparticles and nanomedicines\n## Enhanced permeability and retention (EPR) effect\n## Surface modification for targeted delivery\n# Molecular differences and therapeutic implications","[{\"question\":\"Why is rectal cancer treated differently from colon cancer?\",\"answer\":\"Rectal and colon tumors differ anatomically and molecularly, leading to distinct treatment strategies. Neoadjuvant chemoradiotherapy is pivotal for locally advanced rectal cancer control.\"},{\"question\":\"What is the main obstacle addressed in the review?\",\"answer\":\"Radioresistance remains a major barrier, often correlated with poor prognosis, limiting response to neoadjuvant chemoradiotherapy.\"},{\"question\":\"How can nanoparticles improve radiotherapy outcomes in rectal cancer?\",\"answer\":\"Nanoparticles can exploit the enhanced permeability and retention (EPR) effect for tumor accumulation and can be surface-modified with ligands to enhance targeting, potentially improving radiotherapy response and intratumoral drug delivery.\"}]","Radioresistance in rectal cancer: can nanoparticles turn the tide? | PDF",1790181015,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80f032e3d18a1bc773dab009a42895c1.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5988193f46160db7ce5936cf9edad8cb.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d81ae3880602f2e30f2e42add7dfdb08.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fb9e209a8ae9f8faee3ae8e641d38e9.webp",980,1301]